MSB 12.1% 55.5¢ mesoblast limited

TiGenix and Takeda announce Alofisel® (darvadstrocel) receives...

  1. 333 Posts.
    lightbulb Created with Sketch. 116


    TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn’s disease in Europe

    March 24, 2018 Leuven, Belgium, March 23, 2018 and Osaka, Japan, March 24, 2018, 18:00 CET

    • First allogeneic stem cell therapy to receive central marketing authorization approval in Europe
    • Alofisel offers a new treatment option for patientswho do not respond to current available therapies and may be subject to numerous invasive surgeries1

    TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) and Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the European Commission (EC) has approved Alofisel (darvadstrocel), previously Cx601, for the treatment of complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula.1 This marks the first allogeneic stem cell therapy to receive central marketing authorization (MA) approval in Europe.

    The European approval follows a positive opinion by the European Medicines Agency(EMA) Committee for Medicinal Products for Human Use (CHMP), in conjunction with the Committee for Advanced Therapies (CAT), in December 2017. The recommendation was based on results from TiGenix’s Phase III ADMIRE-CD pivotal trial, which showed that Alofisel achieved statistically significant superiority versus the control group in the primary efficacy endpoint of combined remission at 24 weeks,*1 as well as further follow-up data that indicated Alofisel maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn’s disease over 52 weeks.2

    “I am extremely excited about this approval, which brings allogeneic stem cell therapy one step closer to patients in Europe,” said Professor Julian Panés, Head of the Gastroenterology Department at the Hospital Clinic of Barcelona (Spain) and President of the European Crohn's and Colitis Organisation (ECCO). “Alofisel offers a novel, minimally invasive and well tolerated alternative treatment option for patients with Crohn’s disease who do not respond to currently available therapies, and who have until now had limited treatment options available.”


    “This approval of Alofisel reflects our deep understanding and recognized leadership in the development of allogeneic stem cells and our firm commitment to developing innovative therapies for medical needs," said Dr. María Pascual, VP Regulatory Affairs and Corporate Quality at TiGenix. "We are pleased to offer the medical community an important new treatment option for patients with Crohn’s disease who do not respond to currently available therapies.”

    Alofisel has been licensed to Takeda for the exclusive development and commercialization outside of the US. Receipt of the MA will trigger a milestone payment from Takeda to TiGenix of €15 million, and initiation of the process of transferring MA from TiGenix to Takeda.

    “Today’s marketing authorization, the first for an allogeneic stem cell therapy, represents a positive advancement in the treatment of patients with complex perianal fistulas in Crohn’s disease,” said Dr. Asit Parikh, Head of Takeda’s Gastroenterology Therapeutic Area Unit. “We look forward to bringing this much needed treatment option to patients across Europe in the coming months.”

    The receipt of MA from the EC is one of the conditions to completion of the tender offer announced by Takeda on January 5, 2018.

    The consummation of the tender offer remains subject to other conditions, including the tender into the offer (in Belgium and the US), in aggregate, of a number of shares, warrants and American Depositary Shares that, together with all shares, warrants and American Depositary Shares owned by Takeda and its affiliates, represents or gives access to 85% or more of the voting rights represented or given access to by all of the outstanding shares, warrants and American Depositary Shares of TiGenix on a fully diluted basis as of the end of the initial acceptance period.

    * Combined remission defined as clinical assessment of closure of all treated external openings draining at baseline, despite gentle finger compression, and absence of collections >2cm confirmed by pelvic MRI

    ###

    Contacts

    For TiGenix:

    Claudia Jiménez

    Senior Director

    Investor Relations and Communications

    T: +34 91 804 9264

    [email protected]

    Media enquiries:

    Consilium Strategic Communications

    T: +44 20 3709 5700

    [email protected]

    For Takeda:

    Kazumi Kobayashi

    Media in Japan

    T: +81 33 278 2095

    [email protected]

    Luke Willats

    Media outside of Japan

    T: +41 44 555 1145

    [email protected]

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
0.060(12.1%)
Mkt cap ! $633.0M
Open High Low Value Volume
50.0¢ 59.0¢ 48.5¢ $16.88M 30.80M

Buyers (Bids)

No. Vol. Price($)
7 99223 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.0¢ 44000 4
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
55.5¢
  Change
0.060 ( 15.7 %)
Open High Low Volume
50.5¢ 59.0¢ 48.5¢ 11524458
Last updated 16.02pm 28/03/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.